otiti
media
om
common
diseas
infant
young
children
occur
albeit
less
frequent
older
children
adult
well
hallmark
featur
om
inflamm
middleear
mucosa
without
presenc
effus
airspac
new
om
episod
ie
acut
om
aom
accompani
local
symptom
pain
overt
sign
eg
erythema
bulg
tympan
membran
interpret
evidenc
situ
bacteri
infect
rel
asymptomat
present
yet
unclear
present
repres
differ
underli
etiolog
eg
local
infect
versu
eustachiantub
dysfunct
differ
express
common
etiolog
eg
stage
pathogen
host
respons
aom
progress
andor
predispos
persist
inflammatori
condit
mucosa
om
effus
ome
synonym
secretori
om
glue
ear
recalcitr
standard
medic
therapi
includ
antibiot
antiinflammatori
conduct
hear
loss
usual
accompani
diseas
express
ome
infant
young
children
caus
delay
speech
languag
acquisit
educ
deficit
poor
social
adjust
effus
recov
symptomat
aom
usual
cultureposit
bacteri
pathogen
streptococcu
pneumonia
hemophili
influenza
nontyp
branhamella
catarrhali
common
preantibiot
era
aom
associ
causal
number
potenti
lifethreaten
complic
includ
mening
mastoid
well
sensorineur
hear
loss
current
practic
unit
state
treat
symptomat
aom
antibiot
shown
clinic
studi
erad
bacteri
pathogen
decreas
durat
painrel
symptom
nonetheless
establish
antibiot
treatment
promot
earlier
resolut
mucos
inflamm
abort
diseas
progress
ome
moreov
experi
physician
practic
watch
wait
ie
antibiot
treatment
reserv
aom
episod
signssymptom
fail
resolv
within
period
day
show
episod
aom
selflimit
antibiot
withheld
without
obviou
immedi
consequ
mani
episod
although
wide
adopt
treatment
strategi
expect
reduc
antibiot
use
perhap
decreas
select
pressur
drive
increas
preval
antibioticresist
pathogen
ad
hoc
identif
patient
need
antibiot
treatment
possibl
present
longterm
consequ
practic
respect
possibl
increas
risk
complic
sequela
recurr
known
unit
state
direct
indirect
cost
treat
om
estim
billion
per
year
larg
econom
burden
exist
controversi
current
treatment
aom
ome
diseas
prevent
otiti
media
om
impos
signific
morbid
pediatr
age
group
larg
financi
burden
gener
popul
standard
medic
treatment
highli
efficaci
resolv
accompani
middl
ear
inflamm
goal
current
research
om
prevent
past
studi
show
new
episod
om
usual
complic
viral
upper
respiratori
infect
vuri
therefor
ration
approach
achiev
goal
develop
intervent
strategi
target
vuriassoci
om
howev
past
experi
antibiot
show
absenc
welldefin
treatment
protocol
maxim
expect
efficaci
adopt
prophylact
activ
treatment
om
neg
consequ
patient
gener
popul
review
discuss
hypothes
mechan
vuri
translat
acut
om
episod
describ
differ
strategi
abort
process
limit
deploy
strategi
outlin
primari
goal
regard
number
prophylact
strategi
report
effect
prevent
aom
recurr
aom
highrisk
children
includ
tympanostomi
tube
insert
breastfeed
antibiot
prophylaxi
passiv
immun
hightit
serum
vaccin
bacteri
pathogen
eg
pneumonia
treatment
modifi
bacteri
flora
nasopharynx
eg
adenoidectomi
xylitol
chew
gum
lozeng
nasopharyng
seed
probiot
howev
gener
deploy
strategi
suspect
unanticip
consequ
curtail
enthusiasm
use
best
exemplifi
season
antibacteri
prophylaxi
highrisk
children
intervent
believ
mani
contribut
select
dissemin
pathogen
bacteria
resist
common
increasingli
less
common
antibiot
note
one
wellcontrol
doubleblind
clinic
studi
report
conjug
pneumococc
vaccin
decreas
frequenc
aom
episod
caus
pneumococc
type
bacteria
includ
vaccin
increas
frequenc
om
caus
nonrepres
type
ecolog
nasopharynx
respect
bacteri
adapt
nich
avail
speci
competit
speci
turnov
poorli
understood
implement
strategi
target
specif
eg
antibacteri
immun
nonspecif
eg
antibiot
bacteri
speci
type
strain
site
unintend
consequ
might
detriment
host
andor
gener
popul
although
bacteria
usual
recov
aom
well
accept
onset
episod
tempor
associ
viral
upper
respiratori
tract
infect
vuri
specif
new
om
episod
diagnos
immedi
follow
concurr
symptomat
vuri
convers
aom
occur
approxim
otherwis
healthi
infant
young
children
natur
acquir
vuri
causal
relationship
diseas
support
epidemiolog
studi
document
similar
season
pattern
vuri
aom
other
report
vuri
signific
risk
factor
om
also
upper
respiratori
virus
viral
protein
viral
genom
sequenc
shown
present
high
percentag
effus
recov
aom
episod
disagr
exist
concern
rel
causal
import
aom
differ
upper
respiratori
virus
includ
among
other
respiratori
syncyti
viru
rsv
rhinoviru
adenoviru
influenza
parainfluenza
viru
coxsacki
viru
evid
present
favor
one
viru
convinc
given
bias
introduc
sampl
season
differenti
sensit
employ
viral
assay
rel
skill
laboratori
seem
upper
respiratori
virus
caus
om
well
provok
eustachiantub
dysfunct
underpressur
consid
precondit
om
pathogenesi
direct
support
vuri
causal
aom
provid
anim
studi
report
om
result
adenoviru
influenza
viru
infect
nose
nasopharynx
studi
adult
volunt
report
om
complic
experiment
infect
rhinoviru
influenza
viru
mention
pathogen
bacteria
recov
aom
preclud
primari
viral
etiolog
activ
synergi
certain
upper
respiratori
virus
nasopharyng
pathogen
demonstr
om
pathogenesi
chinchilla
human
preexist
concurr
vuri
infant
children
acut
bacteri
om
frequent
observ
given
evid
causal
intervent
prevent
vuri
andor
prevent
develop
om
vuri
offer
ration
perhap
preferenti
altern
antibiot
treatment
prophylact
strategi
target
bacteri
pathogen
review
discuss
potenti
target
strategi
outlin
practic
variou
option
other
publish
review
topic
differ
emphasi
focu
specif
mechan
om
pathogenesi
vuri
debat
although
viru
usual
recov
cultur
vuriassoci
om
viral
protein
nucleic
acid
detect
high
percentag
effus
use
sensit
assay
interpret
observ
evidenc
local
viral
infect
question
given
lack
proof
virus
replic
within
mucosa
recent
work
show
viral
genom
sequenc
confin
effus
compart
recover
mucos
biopsi
interest
hiv
detect
polymeras
chain
reaction
effus
recov
adult
patient
om
also
seroposit
viru
reason
interpret
deliveri
viru
sequest
within
infiltr
leukocyt
acut
inflamm
similar
mechan
account
detect
viru
protein
nucleic
acid
effus
immedi
follow
vuri
inflammatori
cell
engulf
viru
encount
nose
nasopharynx
home
respons
inflamm
initi
bacteri
infect
neurogen
inflamm
ngi
hydrop
ex
vacuo
caus
hypothesi
consist
exist
data
includ
observ
bacteriaposit
effus
also
contain
viral
genom
sequenc
less
like
resolv
antibiot
therapi
bacteria
alon
presenc
viral
genom
effus
evid
concurr
preexist
vuri
attend
eustachiantub
obstruct
consequ
inhibit
effus
clearanc
review
exist
data
suggest
complic
mechan
om
pathogenesi
vuri
case
cascad
event
precipit
exposur
nasal
mucosa
probabl
local
cellular
infect
viru
upon
viru
detect
local
antigenpres
cell
eg
dendrit
cell
resid
macrophag
viru
interact
epitheli
cell
chemic
compon
innat
immun
system
produc
andor
upregul
eg
defensin
increas
nk
activ
hostalert
cytokin
tumor
necrosi
interferon
synthes
initi
respons
abort
viral
replic
sustain
level
chemic
signal
process
amplifi
genet
program
eg
cytokin
genotyp
environment
tune
eg
chronic
stress
biolog
filter
whose
output
first
caus
synthesi
releas
inflammatori
mediat
eg
histamin
bradykinin
arachidon
acid
metabolit
enhanc
local
influx
effector
chemic
eg
serum
antibodi
leukocyt
second
moder
product
interferon
initi
ngi
coordin
immun
respons
third
modul
upregul
downstream
cytokin
interleukin
il
control
magnitud
durat
immun
inflammatori
respons
synthes
releas
inflammatori
mediat
neurokin
cytokin
interact
posit
neg
feedback
loop
moder
degre
inflamm
specifi
type
primari
magnitud
host
immun
respons
primari
effect
respons
neutral
free
viru
kill
virusinfect
cell
event
signal
product
antiinflammatori
cytokin
chemokin
late
signal
turn
downregul
inflamm
elimin
cellular
debri
promot
mucos
heal
local
tissu
damag
caus
viru
infect
nasal
inflammatori
respons
attribut
host
defens
local
system
effect
variou
chemic
signal
express
symptom
sign
ill
extens
inflamm
without
dissemin
viru
infect
anatom
contigu
structur
eg
eustachian
tube
paranas
sinus
lung
caus
complic
includ
om
sinus
asthmat
exacerb
also
ngi
initi
tissu
damag
upregul
modul
inflammatori
mediat
ngi
amplifi
degre
local
inflamm
thu
promot
effector
compon
influx
site
infect
caus
reflex
inflamm
distal
target
tissu
perhap
anticipationprepar
dissemin
infect
distal
effect
ngi
includ
eustachiantub
dysfunct
increas
mucos
perfus
possibl
consequ
ngi
activ
destabil
pressur
regul
subsequ
develop
signific
underpressur
prolong
om
hydrop
ex
vacuo
secondari
consequ
nasal
infect
certain
upper
respiratori
virus
favor
environ
nasopharyng
growth
specif
bacteri
pathogen
eg
influenza
viru
infect
pneumonia
colon
result
studi
suggest
upregul
antivir
defens
accompani
downregul
antibacteri
defens
effect
serv
free
resid
nasopharyng
pathogen
physiolog
sequestr
therebi
allow
effect
compet
replac
commens
speci
intermitt
relief
viraliniti
underpressur
eustachiantub
open
aspir
nasopharyng
pathogen
caus
situ
bacteri
infect
infect
site
caus
earli
local
synthesi
mucosa
cascad
product
cytokin
mediat
within
turn
chemic
signal
provok
mucos
inflamm
character
om
although
incomplet
previou
descript
highlight
variou
checkpoint
target
prevent
om
vuri
fig
broadli
checkpoint
subdivid
two
gener
class
basi
tempor
dynam
ie
exist
ii
iiiv
establish
viru
infect
nosenasopharynx
obviou
although
somewhat
impract
given
current
demograph
pattern
econom
realiti
unit
state
countri
option
prevent
om
caus
vuri
reduc
probabl
viru
exposur
thu
risk
infect
accomplish
maintain
good
hygien
behavior
social
situat
eg
frequent
hand
wash
daili
nasal
lavag
withdraw
children
high
risk
om
day
care
preschool
enforc
absenc
viru
epidem
strict
adher
rule
send
home
children
teacher
present
day
care
primari
school
signssymptom
coldflu
earli
antivir
treatment
ill
parent
sibl
frequent
contact
date
none
option
explor
clinic
trial
potenti
impact
om
incid
known
one
inher
limit
expect
efficaci
absenc
symptomssign
high
frequenc
person
confirm
upper
respiratori
viru
infect
thu
inabl
identifi
infect
contact
avoid
andor
treatment
altern
om
could
prevent
prime
host
resist
viru
infect
past
studi
show
high
homotyp
serum
igg
antibodi
titer
high
mucos
secretori
igaspecif
antibodi
titer
upregul
immunolog
surveil
eg
natur
killer
function
prevent
infect
reduc
viral
load
diminish
magnitud
signal
chemic
product
decreas
magnitud
frequenc
overt
sign
symptom
vuri
therefor
increas
preexposur
host
level
antibodi
andor
function
activ
tcell
subset
vaccin
andor
immunoglobulin
therapi
could
limit
viral
replic
abort
pathogenesi
vuri
complic
recent
clinic
studi
confirm
efficaci
overal
strategi
specif
number
studi
report
significantli
lesser
incid
infect
target
viru
fewer
associ
om
episod
infant
children
immun
influenza
viru
vaccin
parenter
intranas
rout
pretreat
antirsvenrich
serum
unfortun
although
vaccin
upper
respiratori
virus
develop
test
although
rhinoviru
vaccin
anticip
given
larg
number
circul
type
influenza
vaccin
current
deploy
overal
reduct
om
burden
limit
approxim
also
interpret
result
passiv
immun
enhanc
rsv
antibodi
serum
clearcut
observ
om
reduct
restrict
rsv
season
studi
use
monoclon
antirsv
antibodi
palivizumab
synagi
medimmun
gaithersburg
md
reduc
om
episod
leav
open
possibl
om
prevent
mediat
coexist
antibodi
direct
pathogen
bacteria
within
immun
serum
untest
possibl
prophylact
use
antivir
children
high
risk
om
season
typic
character
infecti
spread
target
viru
viru
identifi
famili
member
andor
regular
contact
eg
classmat
famili
member
howev
prophylact
antivir
treatment
viral
season
might
endang
health
treat
patient
experi
longterm
use
potent
chemic
limit
might
repres
societ
hazard
select
resist
viru
strain
perhap
greater
concern
viru
strain
alter
infecti
andor
trophic
properti
also
interest
possibl
prophylact
use
nonspecif
immun
stimul
upregul
compon
innat
immun
andor
increas
immun
surveil
although
given
controversi
statu
andor
poorli
ration
mechan
action
avail
treatment
eg
homeopath
medicin
practic
applic
approach
lie
futur
also
extent
symptom
sign
ill
vuri
predict
tempor
dynam
infect
resolut
ie
asymptomat
symptomat
person
resolv
infect
although
avail
treatment
target
known
chemic
mediat
effect
promot
symptom
relief
significantli
prolong
period
viral
shed
result
suggest
host
respons
common
upper
respiratori
virus
black
box
fig
includ
virusspecif
immunolog
defens
pathway
requisit
inflammatori
pathway
nonspecif
coincident
inflammatori
pathway
although
requisit
virusspecif
respons
import
prevent
viru
dissemin
reestablish
mucos
health
nonspecif
coincident
inflammatori
respons
caus
unnecessari
symptom
provok
complic
therefor
ideal
vuri
treatment
would
reduc
ill
decreas
complic
attenu
nonspecif
coincident
respons
spare
requisit
respons
ie
pharmacolog
tune
host
respons
approach
requir
much
better
understand
complex
signal
involv
activ
effector
compon
differ
pathway
promis
gener
applic
across
virus
make
pursuit
knowledg
research
prioriti
viral
load
modul
product
chemic
signal
provok
inflamm
earli
antivir
treatment
might
prevent
necessari
precondit
om
one
studi
experiment
influenza
viru
infect
adult
report
significantli
lesser
frequenc
otolog
manifest
ie
abnorm
pressur
group
pretreat
neuraminidas
inhibitor
zanamivir
compar
treat
placebo
contrast
second
studi
model
infect
use
rimantadin
placebo
treatment
begun
time
initi
symptom
report
less
influenza
viru
shed
symptom
ill
nasal
secret
nasal
proinflammatori
cytokin
level
rimantadin
group
treatment
differ
otolog
complic
includ
frequenc
om
discrep
result
two
studi
respect
antivir
efficaci
prevent
otolog
complic
influenza
infect
explic
time
intervent
ie
prophylaxi
vs
treatment
therefor
strategi
might
requir
introduct
antivir
treatment
soon
infect
consequ
preexist
earli
overt
signal
ie
symptomsign
infect
given
specif
antivir
rapid
method
identifi
viru
target
om
prevent
vuri
specif
pathway
uniqu
om
pathogenesi
discuss
earlier
clinic
experiment
data
support
eustachiantub
dysfunct
ie
failur
effect
open
alter
nasopharyng
bacteri
flora
requisit
compon
mechan
vuri
translat
otolog
diseas
caus
eustachiantub
dysfunct
vuri
debat
histolog
studi
chinchilla
document
extens
viru
infect
lumin
mucosa
eustachiantub
function
test
infect
ferret
children
adult
evid
mucos
swell
possibl
caus
ngi
attempt
preserv
adequ
eustachiantub
function
ambient
pressur
vuri
use
oral
decongest
children
adult
success
one
doubleblind
clinic
studi
intranas
steroid
fluticason
propion
administ
day
immedi
onset
vuri
symptom
attempt
decreas
nasopharyng
inflamm
possibl
eustachiantub
obstruct
efficaci
prevent
aom
might
increas
om
incid
rhinoviru
infect
nonetheless
promis
strategi
demonstr
result
random
studi
compar
treatment
influenza
vaccin
tympanostomytub
insert
bypass
eustachian
tube
maintain
ambient
pressur
prevent
om
influenza
season
group
treat
tympanostomi
tube
less
om
group
treat
influenza
vaccin
turn
less
om
untreat
group
howev
signific
limit
pharmacolog
manipul
eustachiantub
function
pauciti
data
regard
drug
effect
function
focu
activ
research
group
sweden
japan
unit
state
altern
vuriassoci
om
could
prevent
target
emerg
extant
nasopharyng
pathogen
mention
vaccin
pneumonia
extend
antibiot
prophylaxi
seed
nasopharynx
probiot
nasopharyng
exposur
xylitol
lozeng
chew
gum
reduc
frequenc
om
episod
adapt
strategi
clinic
studi
design
evalu
prophylact
antibiot
xylitol
administ
limit
period
immedi
symptom
onset
vuri
one
publish
doubleblind
placebocontrol
clinic
studi
xylitol
show
efficaci
prevent
develop
om
vuri
three
studi
use
antibiot
penicillin
v
amoxicillin
clavulan
sultamicillin
doubleblind
placebocontrol
format
demonstr
protect
efficaci
howev
known
treatment
shorten
cours
om
episod
altern
antivir
administ
time
would
effect
possibl
strategi
prevent
om
caus
vuri
includ
intervent
reduc
risk
viru
exposur
reduc
risk
infect
given
viru
exposur
reduc
risk
om
given
viral
infect
note
reduc
exposur
mani
type
circul
upper
respiratori
virus
difficult
circumst
list
option
attent
hygien
within
famili
withdraw
day
care
given
seriou
consider
infant
children
histori
high
risk
recurr
om
breastfeed
well
establish
lessen
latter
two
risk
encourag
infant
perhap
particular
enthusiasm
famili
histori
om
high
risk
vuri
eg
prematur
passiv
immun
hightit
antiviralantibacteri
serum
might
limit
role
prevent
om
caus
viral
andor
bacteri
infect
howev
treatment
option
expens
requir
monthli
administr
inject
associ
pain
possibl
side
effect
might
redund
breastfeed
young
infant
activ
immun
older
infant
children
best
reserv
immunocompromis
infant
children
high
risk
seriou
invas
diseas
eg
rsvassoci
pneumonia
effect
vaccin
target
upper
respiratori
viru
decreas
incid
vuri
reduc
incid
om
current
option
restrict
influenza
vaccin
virus
develop
andor
test
efficaci
remain
demonstr
regulatori
issu
might
delay
introduct
mani
year
attack
rate
differ
virus
caus
vuri
condit
incid
om
per
infect
given
viral
speci
known
effect
immun
number
anticip
viral
vaccin
might
might
signific
impact
om
incid
inform
extrem
import
develop
strategi
prevent
om
caus
vuri
parent
resist
multipl
vaccin
addit
current
requir
recommend
infant
children
expect
impedi
strategi
deploy
also
document
synerg
bacteri
pathogen
caus
om
specif
virus
suggest
immun
virus
might
redund
immun
bacteria
speci
exampl
effici
oper
defin
case
om
prevent
number
individu
treat
influenza
vaccin
om
prevent
expect
decreas
multival
pneumococc
vaccin
becom
univers
given
prevent
pneumococc
om
similar
redund
might
exist
bacteriaviru
combin
om
prevent
viral
vaccin
expect
strategi
applic
rhinoviru
infect
develop
vaccin
reason
valenc
unlik
larg
number
circul
rhinoviru
type
typespecif
host
immun
respons
inabl
neutral
antibodi
access
bind
conserv
capsid
domain
appreci
limit
overal
effici
vaccin
om
prevent
rhinovirus
common
caus
vuri
recogn
frequent
caus
om
rhinoviru
perhap
virus
prevent
infect
andor
presymptomat
treatment
abort
infect
might
requir
prophylact
use
antivir
seri
candid
drug
test
shown
effect
reduc
viral
load
document
infect
howev
deploy
strategi
purpos
prevent
om
share
concern
describ
antibiot
prophylaxi
ie
toxic
sideeffect
patient
select
drugresist
viru
stain
unpredict
properti
rel
long
rhinoviru
season
continu
exposur
differ
rhinoviru
strain
concern
make
strategi
unaccept
gener
use
discuss
wide
varieti
treatment
possibl
could
decreas
om
vuri
howev
option
requir
identifi
signal
indic
infect
preced
develop
om
tempor
relationship
depict
figur
ideal
strategi
target
om
vuri
viral
infect
would
associ
earli
symptomsign
express
magnitud
express
would
suffici
identifi
vuri
ill
om
complic
would
develop
day
detect
ill
signal
therebi
allow
diagnosi
specif
viru
introduct
design
intervent
studi
shown
reallif
situat
fall
far
short
ideal
exampl
experiment
infect
adult
show
time
viral
infect
symptomsign
develop
highli
variabl
across
virus
eg
day
influenza
hrv
day
rsv
infect
magnitud
symptom
sign
cold
flu
like
ill
might
might
achiev
level
suffici
perceiv
signal
infect
experiment
model
absenc
ill
preclud
develop
otolog
complic
fix
tempor
relationship
complic
sign
symptom
present
similarli
young
children
year
natur
symptomat
vuri
approxim
new
om
episod
develop
within
day
day
parent
identif
cold
episod
reason
expect
effici
intervent
om
prevent
begun
vuri
infect
low
propos
strategi
nontarget
applic
expect
rather
low
effici
therefor
ad
hoc
identif
subpopul
prefer
individu
high
risk
om
complic
vuri
would
allow
target
introduct
variou
strategi
om
prevent
therebi
increas
effici
decreas
risk
advers
event
total
cost
om
prevent
high
herit
om
report
famili
histori
import
make
risk
assign
also
preliminari
studi
signific
relationship
report
om
natu
ral
rsv
infect
genotyp
promot
polymorph
result
encourag
continu
studi
genet
om
vuri
promis
avenu
pursu
mani
member
research
commun
express
optim
introduct
vaccin
antivir
effect
virus
predispos
om
soon
assign
om
categori
prevent
diseas
posit
cautiou
emphas
effect
deploy
relat
strategi
requir
care
consider
possibl
impact
individu
societ
health
episod
om
vuri
selflimit
without
signific
longterm
consequ
strategi
reserv
individu
predispos
frequent
diseas
recurr
andor
ome
yet
epidemiolog
om
caus
vuri
complet
develop
eg
virus
import
time
laps
infect
symptom
complic
mechan
underli
om
pathogenesi
fulli
understood
eg
specif
chemic
signal
modul
preserv
host
defens
prevent
om
viru
infect
mucosa
specif
target
popul
aggress
intervent
well
character
remain
research
question
whose
answer
might
might
support
optim
colleagu
respect
make
om
prevent
diseas
